22157.jpg
Source: Research and Markets

Global Pancreatic Cancer Therapy Market Analysis and Forecasts 2017-2025 - Increase in Number of Therapies Launched in the Market

Dublin, Sept. 21, 2018 (GLOBE NEWSWIRE) -- The "Pancreatic Cancer Therapy Market to 2025 - Global Analysis and Forecasts By Type, Therapy and Geography" report has been added to ResearchAndMarkets.com's offering.

The global pancreatic cancer therapy market is expected to reach US$ 4,056.4 Mn in 2025 from US$ 2,011.2 Mn in 2017. The market is estimated to grow with a CAGR of 8.1% from 2018-2025.

The growth of the pancreatic cancer therapy market is primarily attributed to the increase in number of therapies launched in the market. The development of new drugs is thus expected to drive the growth of pancreatic cancer therapy market. For instance, in October 2015, the FDA approved Onivyde drug by Merrimack Pharmaceuticals, Inc. as a part of treatment regimen for advanced pancreatic cancer. Some common side effects associated with chemotherapy drugs include diarrhea and abdominal cramping, fatigue, loss of appetite, change in food taste and others. Cancer cells that are rapidly growing are killed by chemotherapy drugs.


However, these drugs travel throughout the body and thus can affect normal and healthy cells adversely. Blood-forming cells in the bone marrow, hair follicles and cell in the mouth, digestive tract, and reproductive system are likely to be affected by chemotherapeutic drugs. The current treatment options available for pancreatic cancer patients only help to extend the patients' lives by a few months. This demands potential drugs that are able to enhance the effectiveness of chemotherapy drugs. Combination of two or more chemotherapy drugs are a suitable way out to increase the efficacy of the drug as well as proves advantageous in the treatment.


Global pancreatic cancer therapy market, based on the type was segmented into endocrine pancreatic cancer and exocrine pancreatic cancer. In 2017, the exocrine pancreatic cancer segment held the largest share of the pancreatic cancer therapy market, by type. The exocrine pancreatic cancer segment is expected to grow at the fastest rate during the coming years as this cancer is majorly occurring cancer type among the two and thus is expected to have massive patient pool over the forecast years.

Global pancreatic cancer therapy market, based on the therapy was segmented into biologic, chemotherapy and others. In 2017, biologic therapy segment held the largest share of the pancreatic cancer therapy market, by therapy. Moreover, the biologic therapy segment is expected to grow at the fastest rate during the coming years owing to increasing number of novel upcoming immunotherapies as well as targeted cell therapy that treats the cancer without any severe side effects and has number of therapeutic benefits over the conventional chemotherapies.

Some of the major primary and secondary sources for pancreatic cancer therapy included in the report are World Health Organization (WHO), American Society of Clinical Oncology, Pancreatic Cancer Action Network, National Institutes of Health, National Cancer Institute, Scientific American, American Cancer Society and Pancreatic Cancer Research.

Key Topics Covered:

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance

2. Global Pancreatic Cancer Therapy Market - Key Takeaways

3. Global Pancreatic Cancer Therapy Market - Market Landscape
3.1 Overview
3.2 Market Segmentation
3.3 Global Pancreatic Cancer Therapy Market - by Type
3.4 Global Pancreatic Cancer Therapy Market - by Therapy
3.5 Global Pancreatic Cancer Therapy Market - by Geography
3.6 PEST Analysis

4. Global Pancreatic Cancer Therapy Market - Key Market Dynamics
4.1 Key Market Drivers
4.1.1 Rise In Number of Patients Suffering With Pancreatic Cancer
4.1.2 Increasing Healthcare Expenditures For Pancreatic Drugs
4.1.3 Increase In Number of Therapies Launched In the Market
4.2 Key Market Restraints
4.2.1 Side Effects of the Therapies
4.2.2 Low Success Rate of Treatments
4.3 Key Market Opportunities
4.3.1 Development of Efficient Therapy For Pancreatic Cancer Treatment
4.4 Future Trends
4.4.1 Rapid Adoption of Combination Therapy Over Monotherapy
4.5 Impact Analysis

5. Pancreatic Cancer Therapy Market - Global Analysis
5.1 Global Pancreatic Cancer Therapy Market Revenue Forecasts and Analysis
5.2 Global Pancreatic Cancer Therapy Market, by Geography - Forecasts and Analysis
5.3 Expert Opinions

6. Pancreatic Cancer Therapy Market Analysis- by Type
6.1 Overview
6.1.1 Endocrine Pancreatic Cancer
6.1.2 Overview
6.1.3 Global Endocrine Pancreatic Cancer Therapy Market Revenue and Forecasts To 2025 (US$ MN)
6.1.4 Exocrine Pancreatic Cancer

7. Global Pancreatic Cancer Therapy Market Analysis- by Therapy
7.1 Overview
7.2 Biologic Therapy
7.3 Chemotherapy
7.4 Others

8. North America Pancreatic Cancer Therapy Market Revenue and Forecasts To 2025

9. Europe Pancreatic Cancer Therapy Market Revenue and Forecasts To 2025

10. Asia Pacific Pancreatic Cancer Therapy Market Revenue and Forecasts To 2025

11. Middle East and Africa Pancreatic Cancer Therapy Market Revenue and Forecasts To 2025

12. South and Central America Pancreatic Cancer Therapy Market Revenue and Forecasts To 2025

13. Pancreatic Cancer Therapy Market - Industry Landscape
13.1 Overview
13.2 Growth Strategies In the Pancreatic Cancer Therapy Market, 2015-2018
13.3 Organic Developments
13.4 Organic Growth Strategies In the Pancreatic Cancer Therapy Market, 2015-2018
13.5 Clinical Trials
13.6 Product Approval
13.7 Others
13.8 Inorganic Developments
13.9 Inorganic Growth Strategies In the Pancreatic Cancer Therapy Market, 2015-2018
13.10 Collaboration
13.11 Others
13.11.1 Other Organic Developments In the Pancreatic Cancer Therapy Market

14. Pancreatic Cancer Therapy Market - Key Company Profiles

  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Celgene Corporation
  • Amgen Inc.
  • Novartis AG
  • Pharmacyte Biotech Inc.
  • Clovis Oncology
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Merck & Co., Inc.

For more information about this report visit https://www.researchandmarkets.com/research/slzk62/global_pancreatic?w=12


CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Pancreatic Cancer Drugs